Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies
Open Access
- 15 November 2018
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 2616
- https://doi.org/10.3389/fimmu.2018.02616
Abstract
Daratumumab has proven to be highly efficacious for relapsed and refractory multiple myeloma (MM) and has recently been approved in the frontline setting for MM patients ineligible for transplantation. In the future, expanded indications are possible for daratumumab and other anti-CD38 monoclonal antibodies in development. For several years, it has been recognized that these therapies interfere with blood bank testing by binding to CD38 on red blood cells and causing panagglutination on the Indirect Antiglobulin Test. This can lead to redundant testing and significant delays in patient care. Given the anticipated increase in utilization of anti-CD38 monoclonal antibodies, as well as the transfusion needs of MM patients, it is critical to understand the nature of this interference with blood bank testing and to optimize clinical and laboratory procedures. In this review, we summarize the pathophysiology of this phenomenon, examine the clinical data reported to date, describe currently available methods to resolve this issue, and lastly provide a guide to clinical management of blood transfusions for patients receiving anti-CD38 monoclonal antibodies.This publication has 33 references indexed in Scilit:
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyondImmunological Reviews, 2016
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialThe Lancet, 2016
- Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interferencecclm, 2016
- When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapyTransfusion, 2015
- Resolving the daratumumab interference with blood compatibility testingTransfusion, 2015
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myelomamAbs, 2015
- Transfusion of fresh‐frozen plasma in critically ill patients with a coagulopathy before invasive procedures: a randomized clinical trial (CME)Transfusion, 2014
- Risks and adverse outcomes associated with emergency‐release red blood cell transfusionTransfusion, 2012
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsThe Journal of Immunology, 2011
- A Single Protein Immunologically Identified as CD38 Displays NAD+ Glycohydrolase, ADP-Ribosyl Cyclase and Cyclic ADP-Ribose Hydrolase Activities at the Outer Surface of Human ErythrocytesBiochemical and Biophysical Research Communications, 1993